

**NOTE: Revision to
Assay Protocol**

Product Manual


Total Bile Acid Assay Kit

Catalog Number

STA-631

100 assays

**FOR RESEARCH USE ONLY
Not for use in diagnostic procedures**



CELL BIOLABS, INC.
Creating Solutions for Life Science Research

Introduction

Bile is a complex mixture of lipids, protein, carbohydrates, mineral salts, vitamins, and various trace elements, with bile acids making up about 67% of the total composition. Bile acids are produced from excess cholesterol, secreted from the liver, absorbed into the small intestines, and returned to the liver with portal blood. While bile acid synthesis is critical for the removal of cholesterol from the body, bile acids are also needed for proper uptake of dietary lipids, fat soluble vitamins, and other nutrients into the small intestines. Under physiological conditions, newly synthesized bile acids are conjugated to glycine or taurine to form bile salts, and not much free bile acid is actually found in bile.

Determining circulatory levels of bile acids can be used to identify or diagnose certain liver diseases. In addition, elevated serum bile levels have been observed in intrahepatic cholestasis of pregnancy cases.

Cell Biolabs' Total Bile Acid Assay Kit is a simple colorimetric assay that measures the amount of total bile acid present in plasma, serum, tissue homogenates, or cell lysates in a 96-well microtiter plate format. Each kit provides sufficient reagents to perform up to 100 assays, including blanks, bile acid standards and unknown samples. Sample bile acid concentrations are determined by comparison with a known bile acid standard.

Assay Principle

Cell Biolabs' Total Bile Acid Assay Kit measures the total bile acid within serum, plasma, and cell or tissue lysate samples. The assay is based on an enzyme driven reaction: when bile acids are incubated in the presence of 3 α -hydroxysteroid dehydrogenase (3 α -HSD), NADH, and thio-NAD⁺, thio-NAD⁺ is converted to its reduced form Thio-NADH. Thio-NADH is then detected colorimetrically as an absorbance increase at 405 nm (Figure 1).




Figure 1. Total Bile Acid Assay Principle

Related Products

1. STA-367: Human ApoE ELISA Kit
2. STA-369: OxiSelect™ Human Oxidized LDL ELISA Kit (MDA-LDL Quantitation)
3. STA-391: HDL and LDL/VLDL Cholesterol Assay Kit

Kit Components

1. Bile Acid Standard (Part No. 263101): One 200 μ L vial of a 250 μ M glycochenodeoxycholic acid solution in water.
2. Assay Reagent A (Part No. 263102): One 30 mL amber bottle containing thio-NAD⁺.
3. Assay Reagent B (Part No. 263103): Three 1.7 mL vials containing 3 α -HSD and NADH.
4. NADH Reagent (Part No. 263104): Three 1.7 mL vials containing NADH.

Materials Not Supplied

1. 96 well plate or 96 well strips
2. Distilled or deionized water
3. 10 μ L to 1000 μ L adjustable single channel micropipettes with disposable tips
4. 50 μ L to 300 μ L adjustable multichannel micropipette with disposable tips
5. Multichannel micropipette reservoir
6. Microplate Reader

Storage

Upon receipt, store Assay Reagent A at -20°C. Store all other components at -80°C. If the kit will be used in multiple experiments, aliquot each component before freezing to avoid multiple freeze-thaw cycles.

Preparation of Samples

Samples should be assayed immediately or stored at -80°C prior to performing the assay. Optimal experimental conditions for samples must be determined by the investigator. The following recommendations are only guidelines and may be altered to optimize or complement the user's experimental design. A set of serial dilutions is recommended for samples to achieve optimal assay results and minimize possible interfering compounds. Run proper controls as necessary. Always run a standard curve with samples.

- Tissue Lysates: Sonicate or homogenize tissue sample in cold isopropanol and centrifuge at 10,000 x g for 10 minutes at 4°C. Aliquot the supernatant for storage at -80°C. Samples must be diluted at least 5-10-fold in deionized H₂O prior to testing in the assay.
- Cell Lysates: Sonicate or homogenize cells in cold isopropanol and centrifuge at 10,000 x g for 10 minutes at 4°C. Aliquot the supernatant for storage at -80°C. Samples must be diluted at least 5-10-fold in deionized H₂O prior to testing in the assay.
- Serum: Avoid hemolyzed and lipemic blood samples. Collect blood in a tube with no anticoagulant. Allow the blood to clot at room temperature for 30 minutes. Centrifuge at 2500 x g for 20 minutes. Remove the yellow serum supernatant without disturbing the white buffy layer. Aliquot samples for testing and store at -80°C. Perform dilutions in deionized H₂O as necessary.
- Plasma: Avoid hemolyzed and lipemic blood samples. Collect blood with heparin or citrate and centrifuge at 2000 x g and 4°C for 10 minutes. Remove the plasma layer and store on ice. Avoid

disturbing the white buffy layer. Aliquot samples for testing and store at -80°C. Perform dilutions in deionized H₂O as necessary.

Preparation of Bile Acid Standard Curve

Prepare fresh bile acid standards by diluting in deionized H₂O according to Table 1 below.

Tubes	250 μM Bile Acid Standard (μL)	Deionized H₂O (μL)	Resulting Bile Acid Concentration (μM)
1	20	180	25
2	100 of Tube #1	100	12.5
3	100 of Tube #2	100	6.25
4	100 of Tube #3	100	3.12
5	100 of Tube #4	100	1.56
6	100 of Tube #5	100	0.78
7	0	100	0

Table 1. Preparation of Bile Acid Standards.

Assay Protocol

Each Bile Acid standard and sample should be assayed in duplicate or triplicate. A freshly prepared standard curve should be used each time the assay is performed.

Note: Each sample replicate requires two paired wells, one to be treated with 3 α -HSD (Reagent B) and one without the enzyme (NADH).

1. Add 20 μ L of the diluted bile acid standards or samples to the 96-well microtiter plate.
2. Add 150 μ L of Assay Reagent A to each well and mix contents thoroughly.
3. Incubate at 37°C for 5 minutes.
4. Add 50 μ L of Assay Reagent B to the standards and one half of the paired sample wells and mix thoroughly.
5. Add 50 μ L of NADH Reagent to the other half of the paired sample wells and mix the well contents thoroughly.
6. Incubate at 37°C for 30-60 minutes.
7. Read the plate at a primary wavelength of 405 nm and a secondary wavelength 630 nm using a microplate spectrophotometer.

Example of Results

The following figures demonstrate typical Total Bile Acid Assay results. One should use the data below for reference only. This data should not be used to interpret or calculate actual sample results.




Figure 2: Bile Acid Standard Curve.




Figure 3: Mouse Serum tested with the Total Bile Acid Assay kit. Mouse serum samples were tested according to the Assay Protocol.

Calculation of Results

1. Subtract the 630 nm absorbance from the 405 nm absorbance.
2. Determine the average absorbance values for each sample, control, and standard.
3. Subtract the average zero standard value from itself and all standard values.
4. Graph the standard curve (see Figure 2).
5. Subtract the sample well values without 3 α -HSD (NADH) from the sample well values containing enzyme (Assay Reagent B) to obtain the difference. The absorbance difference is due to the enzyme 3 α -HSD activity:

$$\Delta A = A_{RgtB} - A_{NADH}$$

6. Compare the change in absorbance ΔA of each sample to the standard curve to determine and extrapolate the quantity of bile acid present in the sample. Only use values within the range of the standard curve.

References

1. Reshetnyak V.I. (2013) *World J. Gastro.* **19**: 7341-7360.
2. Ambros-Rudolph C.M., Glatz M., Trauner M., Kerl H., and Mullegger R.R., (2007) *Arch. Dermatol.* **143**: 757-762.
3. Angelin B., Bjorkhem I., and Einarsson K. (1978) *J. Lipid Res.* **19**: 527-537.
4. Mashige F., Tanaka N., Maki A., Kami S., and Yamanaka M. (1981) *Clin. Chem.* **27**: 1352-1356
5. Setchell K.D.R., Rodrigues C.M.P., Clerici C., Solinas A., Morelli A., Gartung C., and Boyer J. (1997) *Gastroenterology* 112: 226-235.

Recent Product Citations

1. Ceglia, S. et al. (2023). An epithelial cell-derived metabolite tunes immunoglobulin A secretion by gut-resident plasma cells. *Nat Immunol.* **24**(3):531-544. doi: 10.1038/s41590-022-01413-w.
2. Moreau, F. et al. (2023). Liver-specific FGFR4 knockdown in mice on an HFD increases bile acid synthesis and improves hepatic steatosis. *J Lipid Res.* **64**(2):100324. doi: 10.1016/j.jlr.2022.100324.
3. Mysore, K.R. et al. (2023). Innate immune cell dysfunction and systemic inflammation in children with chronic liver diseases undergoing transplantation. *Am J Transplant.* **23**(1):26-36. doi: 10.1016/j.ajt.2022.09.004.
4. Bhat, N. et al. (2022). TCF7L2 transcriptionally regulates Fgf15 to maintain bile acid and lipid homeostasis through gut-liver crosstalk. *FASEB J.* **36**(3):e22185. doi: 10.1096/fj.202101607R.
5. Alrehaili, B.D. et al. (2022). Bile acid conjugation deficiency causes hypercholanemia, hyperphagia, islet dysfunction, and gut dysbiosis in mice. *HepatoL Commun.* doi: 10.1002/hep4.2041.
6. Blutt, S.E. et al. (2021). Use of Human Tissue Stem Cell-Derived Organoid Cultures to Model Enterohepatic Circulation. *Am J Physiol Gastrointest Liver Physiol.* doi: 10.1152/ajpgi.00177.2021.
7. Reis, L.G. et al. (2021). The Effects of Fermentation of Low or High Tannin Fava Bean-Based Diets on Glucose Response, Cardiovascular Function, and Fecal Bile Acid Excretion during a 28-Day Feeding Period in Dogs: Comparison with Commercial Diets with Normal vs. High Protein. *Metabolites.* **11**(12):878. doi: 10.3390/metabo11120878.
8. Song, Y. et al. (2021). MiR-200c-3p targets SESN1 and represses the IL-6/AKT loop to prevent cholangiocyte activation and cholestatic liver fibrosis. *Lab Invest.* doi: 10.1038/s41374-021-00710-6.
9. Lee, S. W. et al. (2021). Vitamin C deficiency inhibits non-alcoholic fatty liver disease progression through impaired de novo lipogenesis. *Am J Pathol.* doi: 10.1016/j.ajpath.2021.05.020.
10. Liu, Y. et al. (2021). Dysregulated oxalate metabolism is a driver and therapeutic target in atherosclerosis. *Cell Rep.* **36**(4):109420. doi: 10.1016/j.celrep.2021.109420.
11. Rizki-Safitri, A. et al. (2021). Prospect of in vitro Bile Fluids Collection in Improving Cell-Based Assay of Liver Function. *Front. Toxicol.* doi: 10.3389/ftox.2021.657432.
12. Morton, R.E. et al. (2021). The lipid substrate preference of CETP controls the biochemical properties of HDL in fat/cholesterol-fed hamsters. *J Lipid Res.* doi: 10.1016/j.jlr.2021.100027.
13. Velazquez, J.J. et al. (2020). Gene Regulatory Network Analysis and Engineering Directs Development and Vascularization of Multilineage Human Liver Organoids. *Cell Syst.* doi: 10.1016/j.cels.2020.11.002.
14. Steinhauser, C.B. et al. (2020). Lipid metabolism is altered in maternal, placental, and fetal tissues of ewes with small for gestational age fetuses. *Biol Reprod.* doi: 10.1093/biolre/iaaa180.
15. Chandra, A. et al. (2020). Inhibition of microRNA-128-3p attenuates hypercholesterolemia in mouse model. *Life Sci.* doi: 10.1016/j.lfs.2020.118633.

16. Kennedy, L. et al. (2020). Biliary damage and liver fibrosis are ameliorated in a novel mouse model lacking l-histidine decarboxylase/histamine signaling. *Lab Invest.* doi: 10.1038/s41374-020-0405-8.
17. Feng, X. et al. (2020). Depletion of hepatic forkhead box O1 does not affect cholelithiasis in male and female mice. *J Biol Chem.* pii: jbc.RA119.012272. doi: 10.1074/jbc.RA119.012272.
18. Dao Thi, V.L. et al. (2020). Stem cell-derived polarized hepatocytes. *Nat Commun.* **11**(1):1677. doi: 10.1038/s41467-020-15337-2.
19. Kumazaki, S. et al. (2019). Bile Acid Metabolism is an Intermediary Factor between Non-Alcoholic Steatohepatitis and Ischemic Heart Disease in SHRSP5/Dmcr Rats. *J Nutri Food Sci.* **9**:763. doi: 10.35248/2155-9600.19.9.763.
20. Dächert, C. et al. (2019). Gene Expression Profiling of Different Huh7 Variants Reveals Novel Hepatitis C Virus Host Factors. *Viruses.* **12**(1). pii: E36. doi: 10.3390/v12010036.
21. Siemienowicz, K.J. et al. (2019). Fetal androgen exposure is a determinant of adult male metabolic health. *Sci Rep.* **9**(1):20195. doi: 10.1038/s41598-019-56790-4.
22. Torres, S.E. et al. (2019). Ceapins block the unfolded protein response sensor ATF6 α by inducing a neomorphic inter-organelle tether. *Elife.* doi: 10.7554/eLife.46595.
23. Kumar, R. et al. (2019). Bile acid and bile acid transporters are involved in the pathogenesis of acute hepatopancreatic necrosis disease in white shrimp *Litopenaeus vannamei*. *Cell Microbiol.* doi: 10.1111/cmi.13127.
24. Palaniyandi, S.A. et al. (2019). Probiotic Characterization of Cholesterol-Lowering *Lactobacillus fermentum* MJM60397. *Probiotics Antimicrob Proteins.* doi: 10.1007/s12602-019-09585-y.
25. Nikolaou, N. et al. (2019). AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease. *Metabolism.* doi: 10.1016/j.metabol.2019.153947.
26. Argemi, J. et al. (2019). Defective HNF4 α -dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. *Nat Commun.* **10**(1):3126. doi: 10.1038/s41467-019-11004-3.
27. Nakada, E.M. et al. (2019). Conjugated bile acids attenuate allergen-induced airway inflammation and hyperresponsiveness by inhibiting UPR transducers. *JCI Insight.* **4**(9). pii: 98101. doi: 10.1172/jci.insight.98101.
28. Christiansen, C.B. et al. (2019). Bile acids drive colonic secretion of glucagon-like-peptide 1 and peptide-YY in rodents. *Am J Physiol Gastrointest Liver Physiol.* doi: 10.1152/ajpgi.00010.2019.
29. Chevre, R. et al. (2018). Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice. *FASEB J.* **32**(7):3792-3802. doi: 10.1096/fj.201701084RR.
30. Pereira, S.S. et al. (2018). Biliopancreatic diversion with duodenal switch (BPD-DS) and single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) result in distinct post-prandial hormone profiles. *Int J Obes (Lond).* doi: 10.1038/s41366-018-0282-z.

Warranty

These products are warranted to perform as described in their labeling and in Cell Biolabs literature when used in accordance with their instructions. THERE ARE NO WARRANTIES THAT EXTEND BEYOND THIS EXPRESSED WARRANTY AND CELL BIOLABS DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR WARRANTY OF FITNESS FOR PARTICULAR PURPOSE. CELL BIOLABS's sole obligation and purchaser's exclusive remedy for breach of this warranty shall be, at the option of CELL BIOLABS, to repair or replace the products. In no event shall CELL BIOLABS be liable for any proximate, incidental or consequential damages in connection with the products.

Contact Information

Cell Biolabs, Inc.
5628 Copley Drive
San Diego, CA 92111
Worldwide: +1 858 271-6500
USA Toll-Free: 1-888-CBL-0505
E-mail: tech@cellbiolabs.com
www.cellbiolabs.com

©2014-2024: Cell Biolabs, Inc. - All rights reserved. No part of these works may be reproduced in any form without permissions in writing.